Mechanisms of evasion to antiangiogenic therapy in glioblastoma

Clinical Neurosurgery

Volumn 57, Issue , 2010, Pages 123-128

  Rose, Samuel D ^a   Aghi, Manish K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC THERAPY; CELL ASSAY; CONFERENCE PAPER; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MATRIGEL INVASION ASSAY; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ARTICLE; BRAIN TUMOR; CANCER INVASION; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR RECURRENCE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES;

EID: 79952634888     PISSN: 00694827     EISSN: 0148396X     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259. (Pubitemid 46424067)
2. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-4729. (Pubitemid 350086473)
3. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95. (Pubitemid 46075199)
4. Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009;15(10):3617-3623.
5. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
6. Collins TJ. Image J for microscopy. Biotechniques. 2007;43(Suppl 1): 25-30.
7. Said HM, Hagemann C, Staab A, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007; 83(3):398-405. (Pubitemid 46907985)
8. Fukai J, Yokote H, Yamanaka R, Arao T, Nishio K, Itakura T. EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Mol Cancer Ther. 2008;7(9):2768-2778.
9. Wang H, Shen W, Huang H, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 2003;63(15):4315-4321. (Pubitemid 36950996)
10. Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer. 2007;121(2):276-283. (Pubitemid 46917695)
11. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66(8):3987-3991.